Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06185556 |
TitleCOLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases | Phase
Phase 2
|
Date Added 2023-12-29 |
Location
Netherlands
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06176885 |
TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-12-20 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Camrelizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT06152523 |
TitleMonalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer | Phase
Phase 2
|
Date Added 2023-11-30 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Monalizumab/MEDI5257 |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06149481 |
TitlePhase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | Phase
Phase 1, Phase 2
|
Date Added 2023-11-29 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
N-803, Retifanlimab, SX-682 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06120127 |
TitlePostoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence | Phase
Phase 2
|
Date Added 2023-11-07 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Chemotherapy, PD-1 antibody |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06106308 |
TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Phase
Phase 2
|
Date Added 2023-10-30 |
Location
Arizona, United States
Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, FOLFIRI, FOLFOX, Onvansertib |
Tags
MSS/ MMRp
|
| NCT ID NCT06107413 |
TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Phase
Phase 2
|
Date Added 2023-10-30 |
Location
Arizona, United States
Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan Korea, Republic of Spain Taiwan |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan |
Tags
MSS/ MMRp
|
| NCT ID NCT06105021 |
TitlePhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Phase
Phase 1, Phase 2
|
Date Added 2023-10-27 |
Location
California, United States
Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
AFNT-211 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06102902 |
TitleTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC | Phase
Phase 1
|
Date Added 2023-10-26 |
Location
California, United States
Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
BET Bromodomain Inhibitor ZEN-3694, encorafenib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06099821 |
TitleKN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | Phase
Phase 2
|
Date Added 2023-10-25 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
apatinib, KN046, Regorafenib |
Tags
MSI-H/ MMRd
|
